Passage BIO (NASDAQ: PASG) director Derrell Porter receives grant of 10,539 stock options

Rhea-AI Filing Summary

Passage BIO director Derrell Porter received a new stock option grant. The award covers 10,539 options to buy Passage BIO common stock at an exercise price of $5.0800 per share, expiring on May 19, 2036. The option vests in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual stockholder meeting, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Porter Derrell

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	10,539	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 10,539 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 10,539 options Exercise price: $5.0800 per share Underlying shares: 10,539 shares +2 more

5 metrics

Options granted 10,539 options Director stock option grant to Derrell Porter

Exercise price $5.0800 per share Strike price for director stock option grant

Underlying shares 10,539 shares Common stock underlying the options

Post-grant derivative holdings 10,539 options Total options held after this transaction

Option expiration May 19, 2036 Expiration date of the option grant

Key Terms

Director Stock Option (right to buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Director Stock Option (right to buy) financial

"security_title: "Director Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "5.0800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-05-19T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

continuous service financial

"subject to the reporting person's continuous service to the issuer"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Porter Derrell

(Last) (First) (Middle)

ONE COMMERCE SQUARE

2005 MARKET STREET, 39TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Passage BIO, Inc. [ PASG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$5.08	05/19/2026		A		10,539		(1)	05/19/2036	Common Stock	10,539	$0	10,539	D

Explanation of Responses:

1. The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

	/s/ Kathleen Borthwick, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Passage BIO (PASG) report for Derrell Porter?

Passage BIO reported that director Derrell Porter received a grant of 10,539 stock options. These options give him the right to buy common shares at a fixed exercise price as part of his director compensation package, rather than reflecting an open-market trade.

What is the exercise price of Derrell Porter’s Passage BIO stock options?

The granted stock options have an exercise price of $5.0800 per share. This means Porter can buy Passage BIO common stock at this price once the options vest, regardless of the market price at that time, subject to the grant’s terms and conditions.

How many Passage BIO shares are covered by Derrell Porter’s new options?

The grant covers 10,539 stock options, each tied to one share of Passage BIO common stock. After this award, his reported derivative holdings from this grant total 10,539 options, aligning with the number of underlying common shares referenced in the filing.

When do Derrell Porter’s Passage BIO stock options vest?

The options vest in full on the earlier of one year after the grant date or Passage BIO’s 2027 annual stockholder meeting. Vesting is conditioned on Porter’s continuous service to the company through that date, according to the filed footnote explanation.

When do Derrell Porter’s Passage BIO stock options expire?

The stock options expire on May 19, 2036. After that expiration date, any unexercised options from this 10,539-unit grant will lapse and can no longer be used to purchase Passage BIO common stock under the terms disclosed in the filing.